Discounted Cash Flow (DCF) Analysis Levered
Guardion Health Sciences, Inc. (GHSI)
$6.04
-0.02 (-0.33%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 0.44 | 0.94 | 0.90 | 1.89 | 7.23 | 16.33 | 36.89 | 83.30 | 188.11 | 424.79 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -3.40 | -4.17 | -6.03 | -8.01 | -10.64 | -80.37 | -181.50 | -409.88 | -925.61 | -2,090.24 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.04 | -0.31 | -0.17 | -0.04 | -0.07 | -2.08 | -4.69 | -10.59 | -23.92 | -54.02 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -3.44 | -4.48 | -6.20 | -8.05 | -10.72 | -82.45 | -186.19 | -420.47 | -949.53 | -2,144.27 |
Weighted Average Cost Of Capital
| Share price | $ 6.04 |
|---|---|
| Beta | 0.853 |
| Diluted Shares Outstanding | 7,106.57 |
| Cost of Debt | |
| Tax Rate | 0.00 |
| After-tax Cost of Debt | 5.00% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 7.717 |
| Total Debt | 0.03 |
| Total Equity | 42,923.70 |
| Total Capital | 42,923.73 |
| Debt Weighting | 0.00 |
| Equity Weighting | 100.00 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 0.44 | 0.94 | 0.90 | 1.89 | 7.23 | 16.33 | 36.89 | 83.30 | 188.11 | 424.79 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.40 | -4.17 | -6.03 | -8.01 | -10.64 | -80.37 | -181.50 | -409.88 | -925.61 | -2,090.24 |
| Capital Expenditure | -0.04 | -0.31 | -0.17 | -0.04 | -0.07 | -2.08 | -4.69 | -10.59 | -23.92 | -54.02 |
| Free Cash Flow | -3.44 | -4.48 | -6.20 | -8.05 | -10.72 | -82.45 | -186.19 | -420.47 | -949.53 | -2,144.27 |
| WACC | ||||||||||
| PV LFCF | -76.54 | -160.46 | -336.39 | -705.22 | -1,478.42 | |||||
| SUM PV LFCF | -2,757.03 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 7.72 |
| Free cash flow (t + 1) | -2,187.15 |
| Terminal Value | -38,236.93 |
| Present Value of Terminal Value | -26,363.39 |
Intrinsic Value
| Enterprise Value | -29,120.43 |
|---|---|
| Net Debt | -4.07 |
| Equity Value | -29,116.36 |
| Shares Outstanding | 7,106.57 |
| Equity Value Per Share | -4.10 |